Compromised trigemino-coerulean coupling in migraine sensitization can be prevented by blocking beta-receptors in the locus coeruleus.
Adrenergic receptors
Locus coeruleus
Medullary dorsal horn
Migraine
Journal
The journal of headache and pain
ISSN: 1129-2377
Titre abrégé: J Headache Pain
Pays: England
ID NLM: 100940562
Informations de publication
Date de publication:
08 Dec 2023
08 Dec 2023
Historique:
received:
22
08
2023
accepted:
11
11
2023
medline:
8
12
2023
pubmed:
8
12
2023
entrez:
7
12
2023
Statut:
epublish
Résumé
Migraine is a disabling neurological disorder, characterized by recurrent headaches. During migraine attacks, individuals often experience sensory symptoms such as cutaneous allodynia which indicates the presence of central sensitization. This sensitization is prevented by oral administration of propranolol, a common first-line medication for migraine prophylaxis, that also normalized the activation of the locus coeruleus (LC), considered as the main origin of descending noradrenergic pain controls. We hypothesized that the basal modulation of trigeminal sensory processing by the locus coeruleus is shifted towards more facilitation in migraineurs and that prophylactic action of propranolol may be attributed to a direct action in LC through beta-adrenergic receptors. We used simultaneous in vivo extracellular recordings from the trigeminocervical complex (TCC) and LC of male Sprague-Dawley rats to characterize the relationship between these two areas following repeated meningeal inflammatory soup infusions. Von Frey Hairs and air-puff were used to test periorbital mechanical allodynia. RNAscope and patch-clamp recordings allowed us to examine the action mechanism of propranolol. We found a strong synchronization between TCC and LC spontaneous activities, with a precession of the LC, suggesting the LC drives TCC excitability. Following repeated dural-evoked trigeminal activations, we observed a disruption in coupling of activity within LC and TCC. This suggested an involvement of the two regions' interactions in the development of sensitization. Furthermore, we showed the co-expression of alpha-2A and beta-2 adrenergic receptors within LC neurons. Finally propranolol microinjections into the LC prevented trigeminal sensitization by desynchronizing and decreasing LC neuronal activity. Altogether these results suggest that trigemino-coerulean coupling plays a pivotal role in migraine progression, and that propranolol's prophylactic effects involve, to some extent, the modulation of LC activity through beta-2 adrenergic receptors. This insight reveals new mechanistic aspects of LC control over sensory processing.
Sections du résumé
BACKGROUND
BACKGROUND
Migraine is a disabling neurological disorder, characterized by recurrent headaches. During migraine attacks, individuals often experience sensory symptoms such as cutaneous allodynia which indicates the presence of central sensitization. This sensitization is prevented by oral administration of propranolol, a common first-line medication for migraine prophylaxis, that also normalized the activation of the locus coeruleus (LC), considered as the main origin of descending noradrenergic pain controls. We hypothesized that the basal modulation of trigeminal sensory processing by the locus coeruleus is shifted towards more facilitation in migraineurs and that prophylactic action of propranolol may be attributed to a direct action in LC through beta-adrenergic receptors.
METHODS
METHODS
We used simultaneous in vivo extracellular recordings from the trigeminocervical complex (TCC) and LC of male Sprague-Dawley rats to characterize the relationship between these two areas following repeated meningeal inflammatory soup infusions. Von Frey Hairs and air-puff were used to test periorbital mechanical allodynia. RNAscope and patch-clamp recordings allowed us to examine the action mechanism of propranolol.
RESULTS
RESULTS
We found a strong synchronization between TCC and LC spontaneous activities, with a precession of the LC, suggesting the LC drives TCC excitability. Following repeated dural-evoked trigeminal activations, we observed a disruption in coupling of activity within LC and TCC. This suggested an involvement of the two regions' interactions in the development of sensitization. Furthermore, we showed the co-expression of alpha-2A and beta-2 adrenergic receptors within LC neurons. Finally propranolol microinjections into the LC prevented trigeminal sensitization by desynchronizing and decreasing LC neuronal activity.
CONCLUSIONS
CONCLUSIONS
Altogether these results suggest that trigemino-coerulean coupling plays a pivotal role in migraine progression, and that propranolol's prophylactic effects involve, to some extent, the modulation of LC activity through beta-2 adrenergic receptors. This insight reveals new mechanistic aspects of LC control over sensory processing.
Identifiants
pubmed: 38062355
doi: 10.1186/s10194-023-01691-1
pii: 10.1186/s10194-023-01691-1
pmc: PMC10704784
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
165Subventions
Organisme : Agence Nationale de la Recherche
ID : ANR-13-TECS-0005
Organisme : Agence Nationale de la Recherche
ID : ANR-13-TECS-0005
Informations de copyright
© 2023. The Author(s).
Références
Exp Neurol. 2010 Jan;221(1):115-21
pubmed: 19840789
Nat Neurosci. 2017 Nov;20(11):1602-1611
pubmed: 28920933
Ann Neurol. 2006 Apr;59(4):652-61
pubmed: 16450381
Cephalalgia. 2007 Feb;27(2):111-7
pubmed: 17257230
Ann Neurol. 2020 Jun;87(6):939-949
pubmed: 32239542
Pain. 2013 Aug;154(8):1224-36
pubmed: 23718987
Ann Neurol. 2008 Feb;63(2):148-58
pubmed: 18059010
J Neurophysiol. 1986 Nov;56(5):1397-410
pubmed: 3025380
J Headache Pain. 2019 Aug 29;20(1):91
pubmed: 31464579
Brain Res. 1986 Feb 5;364(2):315-30
pubmed: 2868781
Prog Neuropsychopharmacol Biol Psychiatry. 2021 Mar 8;105:110121
pubmed: 33007320
Headache. 2004 Nov-Dec;44(10):961-8
pubmed: 15546258
J Neurosci. 1981 Aug;1(8):876-86
pubmed: 7346592
J Biol Chem. 2006 Jan 13;281(2):1261-73
pubmed: 16280323
Pain. 2014 Jul;155(7):1196-1205
pubmed: 24631586
J Neurosci. 2018 Nov 14;38(46):9934-9954
pubmed: 30249798
Cephalalgia. 2013 Oct;33(13):1096-105
pubmed: 23666930
Brain Res. 1981 Jan 12;204(2):415-20
pubmed: 6257328
Pain. 2007 Apr;128(3):199-208
pubmed: 17084978
Biochem Biophys Res Commun. 2019 Jan 8;508(2):445-450
pubmed: 30503503
Sci Signal. 2017 Jan 24;10(463):
pubmed: 28119465
Brain Res Brain Res Rev. 2003 Apr;42(1):33-84
pubmed: 12668290
Eur J Neurosci. 1995 Jun 1;7(6):1180-7
pubmed: 7582091
Cephalalgia. 1988 Jun;8(2):83-91
pubmed: 3401921
Clin Sci (Lond). 1980 Dec;59 Suppl 6:479s-481s
pubmed: 7449303
Pain. 2019 Feb;160(2):385-394
pubmed: 30371556
J Neurosci. 1996 Aug 15;16(16):5196-204
pubmed: 8756448
Neurobiol Dis. 2013 Dec;60:39-50
pubmed: 23978467
J Neurophysiol. 1994 May;71(5):1752-61
pubmed: 8064346
Int J Mol Sci. 2023 May 06;24(9):
pubmed: 37176049
Pain. 1999 Mar;80(1-2):57-65
pubmed: 10204718
Curr Drug Targets CNS Neurol Disord. 2004 Jun;3(3):239-67
pubmed: 15180484
J Anesth. 2019 Feb;33(1):131-139
pubmed: 30448975
Neurosci Lett. 2000 Sep 22;291(3):139-42
pubmed: 10984626
Cephalalgia. 2011 Jan;31(1):6-12
pubmed: 20974609
Cephalalgia. 2012 Apr;32(5):428-30
pubmed: 22523234
J Neurosci. 2014 Mar 19;34(12):4148-60
pubmed: 24647936
Lancet. 2018 Nov 10;392(10159):1789-1858
pubmed: 30496104
Cephalalgia. 2000 Dec;20(10):907-18
pubmed: 11304026
Prog Neurobiol. 2006 Oct;80(2):53-83
pubmed: 17030082
J Neurophysiol. 1998 Feb;79(2):964-82
pubmed: 9463456
J Neurophysiol. 2011 Jan;105(1):69-87
pubmed: 20980542
Pain. 1983 Jun;16(2):109-110
pubmed: 6877845
Eur J Pharmacol. 1999 Jan 29;366(1):35-9
pubmed: 10064149
Brain Res. 1982 Oct 14;249(2):247-54
pubmed: 7139303
Curr Pain Headache Rep. 2017 Apr;21(4):18
pubmed: 28281109
Biochem J. 1997 Feb 1;321 ( Pt 3):721-8
pubmed: 9032459
Brain Res Bull. 2021 Dec;177:119-128
pubmed: 34543689
Elife. 2017 Oct 13;6:
pubmed: 29027903
Trends Biochem Sci. 2011 Sep;36(9):457-69
pubmed: 21764321
Anesthesiology. 2016 May;124(5):1122-35
pubmed: 26950706
Neurology. 2019 Apr 23;92(17):e2038-e2050
pubmed: 30918090
J Comp Neurol. 2009 Jan 10;512(2):141-57
pubmed: 19003793
Front Neurosci. 2017 May 01;11:243
pubmed: 28507504
Neurosci Lett. 2018 Feb 14;666:120-126
pubmed: 29277624
Eur J Pharmacol. 2001 Jul 13;424(1):53-8
pubmed: 11470260
Prog Cardiovasc Dis. 2004 Jul-Aug;47(1):11-33
pubmed: 15517513
Headache. 2005 Jul-Aug;45(7):926-31
pubmed: 15985111
Brain. 2013 Nov;136(Pt 11):3489-96
pubmed: 24080152
Int J Mol Sci. 2019 Jun 15;20(12):
pubmed: 31208068
Headache. 2006 Feb;46(2):200-7
pubmed: 16492228
Cells. 2022 Aug 06;11(15):
pubmed: 35954288
Nat Neurosci. 2020 Nov;23(11):1376-1387
pubmed: 33020652
Naunyn Schmiedebergs Arch Pharmacol. 1981 Aug;317(1):26-30
pubmed: 6116197
J Neurosci. 1994 May;14(5 Pt 1):2708-23
pubmed: 8182437
J Biol Chem. 2008 Feb 29;283(9):5669-76
pubmed: 18086673
Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):4032-6
pubmed: 11904447
J Neurophysiol. 1999 Mar;81(3):1104-12
pubmed: 10085337
Neuroscience. 1986 Jun;18(2):291-306
pubmed: 3736860
Pain. 2017 Oct;158(10):2025-2034
pubmed: 28700539
Biochem Biophys Res Commun. 2012 Mar 30;420(1):161-5
pubmed: 22405824
Neuroscience. 2016 Dec 3;338:93-113
pubmed: 27267247
Annu Rev Neurosci. 2005;28:403-50
pubmed: 16022602
Neuroreport. 1995 Jul 10;6(10):1363-8
pubmed: 7488725
J Neurophysiol. 2018 May 1;119(5):1658-1664
pubmed: 29361666
Pain. 2012 Jul;153(7):1438-1449
pubmed: 22591831
Cell Tissue Res. 2014 Nov;358(2):443-52
pubmed: 25130141
Mol Pain. 2021 Jan-Dec;17:1744806921997206
pubmed: 33829907
J Pain. 2005 Jul;6(7):439-46
pubmed: 15993822
Biol Psychiatry. 2022 May 1;91(9):786-797
pubmed: 35164940
J Neurophysiol. 1999 Feb;81(2):479-93
pubmed: 10036252
J Neurosci Res. 2017 Jun;95(6):1336-1346
pubmed: 27685982
Eur J Pharmacol. 2013 Sep 15;716(1-3):2-7
pubmed: 23500194
Neurology. 2008 Sep 9;71(11):848-55
pubmed: 18779513